ValueQ3, 24Q4, 24Q1, 25Q2, 25Q3, 25TTMSelling/general/admin expenses12.95 M8.96 M10.92 M40.28 M7.91 M68.06 MResearch & development17.68 M20.53 M13.67 M5.12 M3.96 M43.27 MOperating income30.62 M29.49 M24.59 M45.39 M11.86 M111.33 MNon-Operating Income, Total62 K90 K82 K46 K114 K332 KInterest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses000000Unusual income/expense62 K90 K82 K46 K114 K332 KPretax income30.68 M29.58 M24.67 M45.44 M11.97 M111.66 MEquity in earnings——————Taxes000000Non-controlling/minority interest——————After tax other income/expense——————Net income before discontinued operations27.94 M-34.8 M23.4 M44.22 M10.81 M43.63 MDiscontinued operations——————Net income27.94 M-34.8 M23.4 M44.22 M10.81 M43.63 MDilution adjustment050.09 M00050.09 MPreferred dividends01 0000001 000Diluted net income available to common stockholders27.94 M15.29 M23.4 M44.22 M10.81 M93.72 MBasic earnings per share (Basic EPS)-0.58-0.66-0.48-0.92-0.22-2.28Diluted earnings per share (Diluted EPS)-0.58-0.58-0.48-0.92-0.22-2.2Average basic shares outstanding47.98 M46.33 M48.26 M48.31 M48.31 M191.21 MDiluted shares outstanding47.98 M46.6 M48.26 M48.31 M48.31 M191.48 MEBITDA——————EBIT——————Cost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)260 K332 K200 K200 K200 K932 K
Cassava Sciences Inc
Cassava Sciences is an American pharmaceutical company based in Austin, Texas. The company was developing simufilam, an oral-tablet drug candidate for the treatment of Alzheimer's disease. Development of simufilam was discontinued in November 2024 after it failed to show clinical benefit in phase III clinical trials.
In June 2024, the United States Department of Justice charged an advisor to Cassava Sciences, Hoau-Yan Wang, with fraud over research results related to the experimental drug. Less than a month later, the president, chief executive officer and chairman of the board, Remi Barbier, resigned along with Lindsay Burns, his wife, who was a Cassava senior vice president and Wang's co-author. The U.S. Securities and Exchange Commission filed fraud charges in September 2024 against Cassava, Barbier, Burns and Wang. The parties did not admit wrongdoing, but agreed to pay fines of Cassava $40 million, Barbier $175,000, Burns $85,000, and Wang $50,000. The DOJ dropped the fraud charges against Wang shortly before trial was scheduled to begin in October 2025 without giving a reason.
Cassava was founded in 1998 by Remi Barbier as Pain Therapeutics, Inc., changing its name in 2019.